This product is a second-generation cephalosporin for intravenous or intramuscular injection. It has a wider antibacterial spectrum against Gram-negative bacilli than the first-generation cephalosporin. It has good antibacterial activity similar to cefoxitin against Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Citrobacter, Providencia and Enterobacter, but its activity against indole-positive Proteus, Morganella, Providencia and some Klebsiella is lower than cefoxitin. It has satisfactory activity against influenza bacilli and gonococci (including beta-lactamase-producing strains). Pseudomonas, Serratia and Acinetobacter are resistant to this product. This product is effective against most Gram-positive cocci, and its activity against Staphylococcus aureus is similar to cefoxitin and cefuroxime, but lower than cefoxitin, cephalothin and cefazolin. 90% of the strains can be inhibited by this product at a concentration of 4.0-8.3 mg/L. Most streptococci (including Streptococcus pneumoniae, Streptococcus pyogenes and group B streptococci) are sensitive to this product. Staphylococcus epidermidis is relatively resistant to this product, and faecal streptococci, Staphylococcus aureus and methicillin-resistant strains of Staphylococcus epidermidis are all resistant to this product. The activity of this product against anaerobic bacteria has not been well studied, and Bacteroides fragilis is resistant to this product. The minimum bactericidal concentration (MBC) of this product for Staphylococcus aureus, group B streptococci and Escherichia coli is significantly higher than its minimum inhibitory concentration (MIC). This product is very stable to type I beta-lactamase, but can be slowly hydrolyzed by type IIIa, IIIb and V beta-lactamase, and is sensitive to type IV beta-lactamase.

It has a broad spectrum of antibacterial activity against Gram-positive and Gram-negative bacteria, especially against Escherichia coli, Klebsiella, Haemophilus influenzae, Proteus and Bacteroides fragilis. Its mechanism of action is that it shows a strong affinity for penicillin-binding protein, which is the usual point of action of beta-lactam antibiotics, inhibits cell wall synthesis, binds to peptidoglycan, inhibits the binding of peptidoglycan to lipoprotein to promote bacteriolysis, and shows a strong bactericidal effect in a short time. This product shows antibacterial effect on bacteria during the proliferation period and the early stage of the stable period, and has a bactericidal effect at concentrations lower than the MIC, and lyses bacteria in a short time. The antibacterial effect in vivo is stronger than the prediction of MIC.

It exerts its antibacterial activity by inhibiting the synthesis of bacterial cell walls, and has antibacterial activity against aerobic Gram-positive bacteria (such as Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes) and aerobic Gram-negative bacteria (such as Escherichia coli, Klebsiella pneumoniae, Proteus).

It exerts antibacterial activity by inhibiting the synthesis of bacterial cell walls and has antibacterial activity against aerobic Gram-positive bacteria (such as Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes) and aerobic Gram-negative bacteria (such as Escherichia coli, Klebsiella pneumoniae, Proteus)

It exerts antibacterial activity by inhibiting the synthesis of bacterial cell walls and has antibacterial activity against aerobic Gram-positive bacteria (such as Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes) and aerobic Gram-negative bacteria (such as Escherichia coli, Klebsiella pneumoniae, Proteus)